scholarly journals A selective role for receptor activity‐modifying protein in sub‐chronic action of the amylin selective receptor agonist NN1213 compared to salmon calcitonin on body weight and food intake in male mice

2021 ◽  
Author(s):  
Soraya Arrigoni ◽  
Christelle Le Foll ◽  
Andrea Cabak ◽  
Sofia Lundh ◽  
Kirsten Raun ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Salmon Calcitonin ◽  
Receptor Agonist ◽  
Receptor Activity ◽  
Male Mice

Effects of alarin on food intake, body weight and luteinizing hormone secretion in male mice

Neuropeptides ◽  
2012 ◽  
Vol 46 (2) ◽  
pp. 99-104 ◽  
Author(s):  
Gregory S. Fraley ◽  
Emily Leathley ◽  
Nicole Lundy ◽  
Emily Chheng ◽  
Issurah King ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Luteinizing Hormone ◽  
Hormone Secretion ◽  
Male Mice ◽  
Luteinizing Hormone Secretion

T1808 Increased Food Intake Associated with Decreased Body Weight: Novel Central Metabolic Action of Oligosomatostatin Receptor Agonist in Rats

2009 ◽  
Vol 136 (5) ◽  
pp. A-584
Author(s):  
Andreas Stengel ◽  
Miriam Goebel ◽  
Lixin Wang ◽  
Jean E. Rivier ◽  
Tamer Coskun ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Receptor Agonist ◽  
Metabolic Action

Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats

2007 ◽  
Vol 293 (5) ◽  
pp. R1798-R1808 ◽  
Author(s):  
Prasanth K. Chelikani ◽  
Alvin C. Haver ◽  
Roger D. Reidelberger
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Salmon Calcitonin ◽  
Chronic Administration ◽  
Inhibitory Effect ◽  
Free Access ◽  
Daily Food Intake ◽  
Intraperitoneal Infusion ◽  
Daily Food ◽  
Obese Rats

Chronic administration of anorexigenic substances to experimental animals by injections or continuous infusion typically produces no effect or a transient reduction in daily food intake and body weight. Our aim was to identify an intermittent dosing strategy for intraperitoneal infusion of salmon calcitonin (sCT), a homolog of amylin that produces a sustained 25–35% reduction in daily food intake and adiposity in diet-induced obese rats. Rats (649 ± 10 g body wt, 27 ± 1% body fat), with intraperitoneal catheters tethered to infusion swivels, had free access to a 45% fat diet. Food intake, body weight, and adiposity during the 7-wk test period were relatively stable in the vehicle-treated rats ( n = 16). None of 10 sCT dosing regimens administered in succession to a second group of rats ( n = 18) produced a sustained 25–35% reduction in daily food intake for >5 days, although body weight and adiposity were reduced by 9% (587 ± 12 vs. 651 ± 14 g) and 22% (20.6 ± 1.2 vs. 26.5 ± 1.1%), respectively, across the 7-wk period. The declining inhibitory effect of sCT on daily food intake with the 6-h interinfusion interval appeared to be due in part to an increase in food intake between infusions. The declining inhibitory effect of sCT on daily food intake with the 2- to 3-h interinfusion interval suggested possible receptor downregulation and tolerance to frequent sCT administration; however, food intake increased dramatically when sCT was discontinued for 1 day after apparent loss of treatment efficacy. Together, these results demonstrate the activation of a potent homeostatic response to increase food intake when sCT reduces food intake and energy reserves in diet-induced obese rats.

Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats

2001 ◽  
Vol 281 (2) ◽  
pp. R444-R451 ◽  
Author(s):  
Joyce J. Hwa ◽  
Lorraine Ghibaudi ◽  
Jun Gao ◽  
Eric M. Parker
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Receptor Agonist ◽  
Melanocortin Receptor ◽  
Zucker Rats ◽  
Light Cycle ◽  
Weight Regulation ◽  
Central Administration ◽  
Body Weight Regulation ◽  
Obese Zucker Rats

Melanocortins play a critical role in appetite and body weight regulation, because manipulations of this pathway can lead to the development of obesity in several animal models. The purpose of this study was to use a melanocortin receptor agonist and antagonist to evaluate the involvement of melanocortins in feeding, energy metabolism, and body weight regulation in lean and obese Zucker rats. Central administration of a melanocortin receptor antagonist (SHU9119) elevated food intake and body weight of lean Zucker rats but had little effect in obese Zucker rats. In contrast, the melanocortin receptor agonist MTII reduced food intake in both lean and obese rats but was more potent in the obese Zucker rats. These data indicate the existence of functional melanocortin receptors in both lean and obese Zucker rats but suggest that obese Zucker rats have reduced endogenous melanocortin tone. In addition to its effects on food intake, MTII infusion elevated oxygen consumption and decreased respiratory quotient dose dependently during the light cycle. Our data suggest that a melanocortin receptor agonist can induce weight loss by increasing energy expenditure and promoting body fat utilization in addition to its inhibitory effects on food intake in both obese and lean Zucker rats.

scholarly journals Fat Mass Regain in Middle-Aged Mice after Sleeve Gastrectomy is divergent from plasma leptin levels

2020 ◽  
Author(s):  
Ana BF Emiliano ◽  
Ying He ◽  
Sei Higuchi ◽  
Rabih Nemr ◽  
Natalie Lopatinsky ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Fat Mass ◽  
Male Mice ◽  
Middle Aged ◽  
Sham Surgery ◽  
Sh Group ◽  
Plasma Leptin ◽  
Obese Male ◽  
Cumulative Food Intake

AbstractBackgroundSome degree of weight regain is typically observed in human patients who undergo Sleeve Gastrectomy (SG), even if the majority of them do not return to their presurgical body weight. Although the majority of bariatric surgery patients are middle aged, most preclinical models of bariatric surgery utilize juvenile male mice. A long-term characterization of the response of mature, wild type, obese male mice to SG has not been performed.MethodsEight-month old C57bl/6J obese male mice were randomized to undergo SG, sham surgery without caloric restriction (SH) or sham surgery with caloric restriction to match body weight to the SG group (SWM). Body weight, body composition and glucose tolerance were matched at baseline. Mice were followed for 60 days following their respective surgeries.ResultsSG mice had a more pronounced percent weight loss than the SH group in the first post-operative month (p<0.05), along with fat mass loss (p<0.01). By the second post-operative month, the SG group started to regain fat mass, although it continued to be statistically lower than the SH group (p<0.05). Cumulative food intake was significantly lower in the SG group compared to SH group only in the first post-operative week (p<0.05), with both groups having similar cumulative food intake thereafter (p>0.05). SWM group had a significantly lower cumulative food intake throughout the study, except for week 1 (p<0.01). Glucose tolerance was only demonstrably better in the SG group compared to SH group at 8 weeks post-operatively (p<0.01). Plasma leptin was significantly lower in the SG group compared to both SWM and SH groups group by the second post-operative month (p<0.01), in spite of SG’s increasing fat mass accumulation. In the second post-operative month, both FGF-21 and GDF-15 were increased in the SH group compared to the SG and SWM groups (p<0.05), while there was no difference in plasma insulin among the three groups. Heat production was surprisingly higher in the SH group compared to the other two groups (p<0.05), even though brown adipose tissue Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Cidea mRNA expression were significantly higher in SG and SWM compared to SH (p<0.01). There was no change in BAT UCP-1 mRNA expression among the groups (p>0.05). There was also no change in fecal lipid content among the groups (p>0.05).ConclusionsSG in obese, middle aged male mice leads is accompanied by fat mass regain in the second post-operative month, while plasma leptin levels continue to be significantly lower. This raises the question of whether the observed fat mass regain consists mostly of visceral adipose tissue.

The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats

2021 ◽  
Author(s):  
Lauren M. Stein ◽  
Lauren E McGrath ◽  
Rinzin Lhamo ◽  
Kieran Koch-Laskowski ◽  
Samantha M. Fortin ◽  
...  
Keyword(s):  
Body Weight ◽  
Weight Gain ◽  
Energy Balance ◽  
Food Intake ◽  
Energy Intake ◽  
Receptor Agonist ◽  
Body Weight Gain ◽  
Male Rats ◽  
Calcitonin Receptor ◽  
Long Acting

The peptide hormone amylin reduces food intake and body weight, and is an attractive candidate target for novel pharmacotherapies to treat obesity. However, the short half-life of native amylin and amylin analogs like pramlintide limits these compounds' potential utility in promoting sustained negative energy balance. Here, we evaluate the ability of the novel long-acting amylin/calcitonin receptor agonist ZP5461 to reduce feeding and body weight in rats, and also test the role of calcitonin receptors (CTRs) in the dorsal vagal complex (DVC) of the hindbrain in the energy balance effects of chronic ZP5461 administration. Acute dose-response studies indicate that systemic ZP5461 (0.5-3 nmol/kg) robustly suppresses energy intake and body weight gain in chow- and high-fat diet (HFD)-fed rats. When HFD-fed rats received chronic systemic administration of ZP5461 (1-2 nmol/kg), the compound initially produced reductions in energy intake and weight gain, but failed to produce sustained suppression of intake and body weight. Using virally-mediated knockdown of DVC CTRs, the ability of chronic systemic ZP5461 to promote early reductions in intake and body weight gain was determined to be mediated in part by activation of DVC CTRs, implicating the DVC as a central site of action for ZP5461. Future studies should address other dosing regimens of ZP5461 to determine whether an alternative dose/frequency of administration would produce more sustained body weight suppression.

Sign in / Sign up

Export Citation Format

Share Document